Entering text into the input field will update the search result below

Hepion Pharmaceuticals gets FDA fast track designation for CRV431 to treat liver disease

Nov. 30, 2021 8:56 AM ETHepion Pharmaceuticals, Inc. (HEPA) StockBy: Ravikash Bakolia, SA News Editor1 Comment
  • The U.S. Food and Drug Administration granted fast track designation to Hepion Pharmaceuticals (HEPA) lead drug candidate CRV431 to treat non-alcoholic steatohepatitis (NASH), a type of liver disease.
  • “CRV431 has been investigated in healthy subjects during our Phase 1 program, and more

Recommended For You

About HEPA Stock

SymbolLast Price% Chg
Market Cap
PE
Yield (TTM)
Rev Growth (YoY)
Prev. Close
Compare to Peers

Related Stocks

SymbolLast Price% Chg
HEPA--
Hepion Pharmaceuticals, Inc.